Alembic Pharmaceuticals informs about press release
Alembic Pharmaceuticals has informed that it enclosed press release titled ‘Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.’
The above information is a part of company’s filings submitted to BSE.
